Insys Therapeutics (INSY) Trading Up 7.8%

Insys Therapeutics (NASDAQ:INSY)’s share price was up 7.8% on Tuesday . The company traded as high as $6.98 and last traded at $6.76. Approximately 1,037,737 shares were traded during trading, a decline of 18% from the average daily volume of 1,264,421 shares. The stock had previously closed at $6.27.

A number of equities analysts recently weighed in on INSY shares. Zacks Investment Research cut Insys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd. ValuEngine raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Oppenheimer reissued a “hold” rating on shares of Insys Therapeutics in a report on Sunday, March 11th. Piper Jaffray cut Insys Therapeutics from a “neutral” rating to an “underweight” rating in a report on Friday, March 9th. Finally, Cann reissued an “average” rating on shares of Insys Therapeutics in a report on Friday, March 2nd. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Insys Therapeutics has an average rating of “Hold” and an average price target of $9.38.

How to Become a New Pot Stock Millionaire

The firm has a market cap of $448.49, a price-to-earnings ratio of -13.80 and a beta of 1.13.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.47). The firm had revenue of $31.49 million for the quarter, compared to analysts’ expectations of $34.00 million. Insys Therapeutics had a negative net margin of 162.07% and a negative return on equity of 24.02%. The business’s quarterly revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 earnings per share. analysts forecast that Insys Therapeutics will post -0.83 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Stone Ridge Asset Management LLC purchased a new position in Insys Therapeutics in the 4th quarter worth approximately $137,000. Schwab Charles Investment Management Inc. increased its stake in Insys Therapeutics by 31.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 104,812 shares of the specialty pharmaceutical company’s stock worth $931,000 after purchasing an additional 24,869 shares during the period. Wells Fargo & Company MN increased its stake in Insys Therapeutics by 50.1% in the 3rd quarter. Wells Fargo & Company MN now owns 41,516 shares of the specialty pharmaceutical company’s stock worth $368,000 after purchasing an additional 13,849 shares during the period. Virtu Financial LLC increased its stake in Insys Therapeutics by 96.8% in the 4th quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock worth $193,000 after purchasing an additional 9,866 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in Insys Therapeutics in the 3rd quarter worth approximately $135,000. 24.05% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Insys Therapeutics (INSY) Trading Up 7.8%” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/04/17/insys-therapeutics-insy-trading-up-7-8.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply